Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Inhaled BHT Excipient in Healthy and Asthmatic Adults
NCT02220673Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2009
- Primary completion
- May 2010
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of butylated hydroxytoluene in asthma (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Maximum decrease of forced expiratory volume in one second. Started Nov 2009; status: completed.
02
Drugs
butylated hydroxytoluene
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02220673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02220673.